Springworks Therapeutics, Inc. Stock Price, News & Analysis

SpringWorks Therapeutics (Nasdaq: SWTX) announced the appointment of James Cassidy, M.D., Ph.D., as its new Chief Medical Officer, succeeding Jens Renstrup, M.D., MBA. Dr. Cassidy brings over 30 years of oncology experience, including significant roles at Regeneron, Celgene, and Bristol-Myers Squibb. His leadership is expected to enhance SpringWorks' targeted oncology focus. The company continues to advance its differentiated portfolio, with ongoing clinical trials for rare tumors and genetically defined cancers.

SpringWorks Therapeutics (Nasdaq: SWTX) announced the issuance of U.S. Patent No. 11,066,358 for mirdametinib, which is under development for multiple oncology indications, including NF1-associated plexiform neurofibromas (NF1-PN). This patent, expiring in 2041 and assigned to Pfizer, enhances patent protection for the compound. CEO Saqib Islam emphasized the importance of this patent in their strategy to expand intellectual property for targeted oncology treatments. Mirdametinib is currently in clinical trials for various cancer types, with over 250 subjects having been treated.

Precision BioSciences (DTIL) and SpringWorks Therapeutics (SWTX) announced that the first patient has been dosed in their Phase 1/2a trial combining PBCAR269A, an allogeneic CAR T cell therapy targeting BCMA, with nirogacestat, a gamma secretase inhibitor, for treating relapsed/refractory multiple myeloma.

Precision is also gearing up to share interim results from monotherapy studies and plans to progress PBCAR269B into clinical trials in 2022, highlighting their commitment to developing innovative therapies.

SpringWorks Therapeutics (Nasdaq: SWTX) has initiated a Phase 1/2 clinical trial for mirdametinib, a MEK inhibitor targeting low-grade glioma (LGG) in pediatric patients. Sponsored by St. Jude Children’s Research Hospital, the trial aims to assess the safety and efficacy of mirdametinib in children and young adults aged 2 to 24. With over 250 previous subjects treated, mirdametinib shows promise in addressing the unmet medical needs of pediatric LGG, which lacks FDA-approved therapies. The study will enroll up to 130 patients, offering hope for improved outcomes in this challenging condition.

SpringWorks Therapeutics (Nasdaq: SWTX) announced encouraging interim data from the Phase 2b ReNeu trial of mirdametinib, an investigational MEK inhibitor for NF1-associated plexiform neurofibromas (NF1-PN). Presented at the 2021 Children’s Tumor Foundation NF Conference, the update showed that 50% of the first 20 adult patients achieved a ≥20% reduction in tumor volume, with 80% remaining on treatment after 12 months. Mirdametinib was generally well tolerated, with adverse events primarily at Grade 1 or 2 levels. The trial aims to complete enrollment in late 2021.

SpringWorks Therapeutics (Nasdaq: SWTX) announced a clinical trial collaboration with Seagen Inc. to evaluate nirogacestat, a gamma secretase inhibitor, combined with Seagen's SEA-BCMA monoclonal antibody for treating multiple myeloma. Nirogacestat aims to enhance BCMA-targeted therapies by increasing membrane-bound BCMA. Seagen will conduct the Phase 1 study, with costs covered, and a joint committee will oversee it. SpringWorks is also conducting a Phase 3 trial for nirogacestat as a monotherapy for desmoid tumors and has received FDA orphan drug designation.

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company specializing in rare diseases and cancer treatments, announced participation in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. The event is scheduled for 3:00 PM ET. Interested parties can access the live webcast via the company’s Investors & Media section. A recording will be available afterward. SpringWorks is advancing clinical trials for targeted oncology therapies and has formed partnerships to enhance its portfolio.

SpringWorks Therapeutics (Nasdaq: SWTX) announced its participation in a Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit on May 21, 2021, at 10:00 AM ET. The event aims to highlight the company’s efforts in developing medicines for rare diseases and cancer. Interested parties can access the live webcast through the company’s website, with a replay available afterward. SpringWorks is known for its precision medicine approach and is advancing clinical trials for targeted oncology product candidates.

SpringWorks Therapeutics (Nasdaq: SWTX) announced the appointment of Mike Burgess, M.B.Ch.B., Ph.D. as Head of Research and Development, effective immediately. Dr. Burgess brings over 20 years of R&D leadership in oncology, most recently as President of R&D at Turnstone Biologics. He succeeds Stephen Squinto, Ph.D., who will remain on the Board of Directors. This leadership change is strategic as SpringWorks aims to enhance its oncology pipeline and develop life-changing therapies for cancer patients.